首页 | 本学科首页   官方微博 | 高级检索  
     

托伐普坦对急性充血性心力衰竭合并慢性肾功能不全患者的治疗效果
引用本文:刘燕飞,王剑,尹磊. 托伐普坦对急性充血性心力衰竭合并慢性肾功能不全患者的治疗效果[J]. 中国临床药理学杂志, 2021, 0(6): 655-657
作者姓名:刘燕飞  王剑  尹磊
作者单位:长沙市第四医院心血管二科
摘    要:目的 观察托伐普坦对急性充血性心力衰竭合并慢性肾功能不全的治疗效果.方法 将60例患者依据随机数字法分为对照组30例与试验组30例.对照组在常规抗心力衰竭的基础上给予呋塞米注射液,每次20 mg,qd,静脉注射.试验组在常规抗心力衰竭的基础上给予托伐普坦片,每次30 mg,qd,口服.2组治疗时间均为7 d.对比2组患...

关 键 词:托伐普坦  充血性心力衰竭  慢性肾功能不全  利尿剂

Therapeutic effect of tolvaptan on acute congestive heart failure combined with chronic renal insufficiency
LIU Yan-fei,WANG Jian,YIN Lei. Therapeutic effect of tolvaptan on acute congestive heart failure combined with chronic renal insufficiency[J]. The Chinese Journal of Clinical Pharmacology, 2021, 0(6): 655-657
Authors:LIU Yan-fei  WANG Jian  YIN Lei
Affiliation:(Department of Cardiology,the Fourth Hospital of Changsha,Changsha 410006,Hunan Province,China)
Abstract:Objective To observe the therapeutic effect of tolvaptan on acute congestive heart failure combined with chronic renal insufficiency.Methods According to the random number method,60 patients were divided into control group with 30 cases and treatment group with 30 cases.Control group was given furosemide injection,20 mg each time,qd,intravenously on the basis of conventional anti-heart failure treatment.Treatment group was treated with conventional anti-heart failure therapy and tolvaptan tablets 30 mg each time,qd,orally.The treatment time of both groups was 7 d.The left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD),serum sodium(Na+),serum potassium(K+),serum creatinine(Scr),blood urea nitrogen(BUN),renal small sphere filtration rate(GFR),clinical efficacy,adverse drug reactions in two groups were compared.Results After treatment,the effective rates of treatment group and control group were 96.67%(29 cases/30 cases)and 73.33%(22 cases/30 cases),with significant difference(P<0.05).After treatment,the LVEF in treatment group and control group were(45.89±3.28)%and(43.58±3.11)%,LVEDD were(44.32±3.07)and(47.15±4.25)mm,Scr were(154.69±20.11)and(186.41±20.51)μmol·L-1,BUN were(9.67±1.06)and(11.53±1.50)mmol·L-1,GFR were(47.15±2.27)and(42.69±2.33)m L·(min·1.73 m2)-1,the data were all with significant difference(all P<0.05).The incidence of adverse drug reactions in treatment group and control group during treatment were 3.33%and 10.00%,without significant difference(P>0.05).Conclusion Using tolvaptan as the main strategy for the treatment of patients with acute congestive heart failure combined with chronic renal insufficiency,which helped improve heart function,corrected electrolyte disturbances,prevent deterioration of renal function,and improved the treatment effect in the short term,with good safety.
Keywords:tolvaptan  congestive heart failure  chronic renal insufficiency  diuretics
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号